Research

Biomedical research: improving disease knowledge

The biomedical research is the key for understanding the molecular mechanisms that harbor in the disease and also use them to identify new target for novel treatments.

I completed the Grade in Biology in 2006 at the University of Navarra, focusing on Molecular and Health biology. My aim was to point in Genetics and its therapeutic applications; therefore, I join up to the Biochemistry and Genetics Department focused on researching about cytogenetic and molecular diagnosis of haematologic and oncologic diseases.

I enrolled in the Cellular and Molecular PhD programme in the Center of Applied Medical Research (CIMA; University of Navarre) where I developed a research in the field of Characterization of genomic biomarkers in early-staged Non-Small Cell Lung Cancer (NSCLC) patients using SNP (Single nucleotide polymorphisms) microarays. The bioinformatic analysis was carried out as visiting researcher in the BROAD Institute y Dana-Farber Cancer Institute de Harvard Medical School (Boston, USA).

Complementary to my oncology training, I participate actively in several research projects in the Translational Oncology Lab of the Health Research Institute in Hospital Fundación Jiménez Díaz (Madrid).

Biomedical Research Projects:

  • Characterization of genomic biomarker with prognostic value in Early stage Non-small cell lung cancer (NSCLC) patients by SNP arrays (Single nucleotide polymorphisms).
  • Clinical characterization of an Early stage Non-small cell lung cancer (NSCLC) patient’s cohort treated with pulmonal lobectomy.
  • Clinical and molecular characterization of Gastrointestinal Stromal Tumors (GIST) patients: Novel therapeutic targets and predictive molecular subgroups.
  • Tumor microenvironment in patients diagnosed of melanoma as a predictive biomarker to standard treatment.
  • Clinical and tumor microenvironment characterization of Immunotherapy-related toxicity in Metastatic Lung Cancer patients.
  • Clinical significance of small RNA molecules in patients diagnosed od Pancreas Adenocarcinoma.
This website uses its own and third party cookies. By accepting, you consent to its use. If you want to know more about the privacy policy of your data and cookies, click on "More info"
More info